CombiMatrix gains $2.2m US funding:
This article was originally published in Clinica
The US Department of Defense (DoD) has awarded a one-year, $2.2m contract to CombiMatrix to fund the further development of its microarrays for a multipathogen- and chemical-detection system, using its "on chip" electrochemical detection process. The Newport Beach, California company has demonstrated that its products can simultaneously detect toxins, viruses and bacteria using its semiconductor-based microarrays, under previously DoD-funded research programmes. These systems are currently in use at several military and government laboratories as well as civilian installations.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.